Stocktoria
SCYNEXIS INC SCYX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-05-02
SCYNEXIS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $20.6M | $3.7M | $140.1M | $5.1M | $13.2M |
| R&D expense | $22.3M | $26.4M | $30.9M | $27.3M | $23.8M |
| SG&A expense | $14.4M | $14.5M | $20.9M | $63.0M | $49.9M |
| Operating income | -$16.1M | -$37.1M | $72.7M | -$85.8M | -$60.8M |
| Interest expense | — | — | $3.1M | $5.2M | $2.7M |
| Income tax | $0 | $151,000 | $138,000 | -$4.7M | -$3.1M |
| Net income | -$8.6M | -$21.3M | $67.0M | -$62.8M | -$32.9M |
| EPS (diluted) | $-0.17 | $-0.44 | $1.39 | $-1.47 | $-1.25 |
| Operating cash flow | -$5.3M | -$24.0M | $60.2M | -$79.9M | -$54.6M |
| Free cash flow | — | — | — | — | -$54.6M |
| Cash & equivalents | $21.3M | $16.1M | $34.0M | $45.8M | $104.5M |
| Inventory | — | — | $0 | $899,000 | $463,000 |
| Total assets | $59.0M | $90.6M | $128.4M | $87.8M | $119.8M |
| Total liabilities | $9.7M | $35.6M | $55.5M | $84.6M | $78.6M |
| Shareholders' equity | $49.4M | $55.1M | $73.0M | $3.2M | $41.3M |
Source: SEC EDGAR filings · CIK 0001178253 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.